Blog

Journal of Commercial Biotechnology This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

Financial accounts reports

Go to paper

ABSTRACT: Basilea Pharmaceutica AG is a Swiss-based biotechnology company whose shares are traded on the Swiss Stock Exchange. It is developing antibacterial and antifungal drugs along with dermatology treatments. The company was founded in October 2000 as a wholly owned subsidiary of F. Hoffmann-La Roche, which subsequently sold over half of the company's shares to other investors but retained approximately 33 per cent of the company at 31st December, 2004...

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

  • Management
  • Policy
  • Finance
  • Law
  • Regulation
  • Bioethics

For more information, see the Journal of Commercial Biotechnology website

Journal of Commercial Biotechnology This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

Financial accounts reports

Go to paper

ABSTRACT: Basilea Pharmaceutica AG is a Swiss-based biotechnology company whose shares are traded on the Swiss Stock Exchange. It is developing antibacterial and antifungal drugs along with dermatology treatments. The company was founded in October 2000 as a wholly owned subsidiary of F. Hoffmann-La Roche, which subsequently sold over half of the company's shares to other investors but retained approximately 33 per cent of the company at 31st December, 2004...

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

  • Management
  • Policy
  • Finance
  • Law
  • Regulation
  • Bioethics

For more information, see the Journal of Commercial Biotechnology website

The Journal of Commercial Biotechnology is seeking applications for the position of Managing Editor.

Responsibilities

The Journal of Commercial Biotechnology has been described as “a Harvard Business Review for Biotechnology Companies.” The Managing Editor should seek to maintain this editorial focus and strong standing through:

– Solicitation of papers in line with the JCB’s editorial focus

– Managing peer review of submitted papers

– Writing editorials in timely biotechnology industry topics

– Representing the JCB at conferences

Experience

This is a part-time post.

The ideal candidate will have primary appointment at a top-flight academic institution, or a commercial enterprise with the ability to dedicate time to meeting the responsibilities noted above.

About the Journal of Commercial Biotechnology

The Journal of Commercial Biotechnology, in print since 1994, is the definitive international quarterly publication for bioscience business professionals. The Journal is designed specifically for those professionals who need to enhance their knowledge of biotechnology business strategy and management, improve and advance their product development or want to keep up-to-date with current issues and industry trends.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

  • Management
  • Policy
  • Finance
  • Law
  • Regulation
  • Bioethics

To Apply

Send a cover letter using the contact form at thinkbiotech.com.

DrugPatentWatch provides competitive intelligence on small-molecule drugs and the 90,000 global patents covering them

Click the patents below for more details, or visit DrugPatentWatch.com for more options.

LAMISIL (terbinafine)
Novartis
Patent number: 5,681,849
Expiration Date: Apr 28, 2015


LAMISIL AT (terbinafine hydrochloride)
Novartis
Patent number: 5,681,849
Expiration Date: Apr 28, 2015


LAMISIL AT (terbinafine)
Novartis
Patent number: 5,681,849
Expiration Date: Apr 28, 2015


MAVIK (trandolapril)
Abbvie
Patent number: 5,744,496
Expiration Date: Apr 28, 2015


For more information try a free trial

TechTransferWatch is a search engine and alert service for licenseable technologies from academic labs, foundations, and government.

Click the patents below for more details, or visit TechTransferWatch.com for more options.

Soybean variety ‘G04-1618RR’
University of Georgia
Patent number: 9,018,455
Issue Date: April 28, 2015


Non-diffusing plant virus vector
Noriho Fukuzawa, Takeshi Matsumura, Noriko Itchoda, Takeaki Ishihara, Chikara Masuta, Noriho Fukuzawa, Takeshi Matsumura, Noriko Itchoda, Takeaki Ishihara, Chikara Masuta
Japan National Institute of Advanced Industrial Science and Technology
Patent number: 9,018,444
Issue Date: April 28, 2015


Antisense oligonucleotides for inducing exon skipping and methods of use thereof
University of Western Australia
Patent number: 9,018,368
Issue Date: April 28, 2015


Single stranded DNA aptamers binding NF-κB/RelA
Steven G. Widen, Thomas G. Wood, Allan R. Brasier, Yingxin Zhao
University of Texas System
Patent number: 9,018,367
Issue Date: April 28, 2015


DC-STAMP antibodies
Edward M. Schwarz, Kofi A. Mensah, Yahui Grace Chiu, Christopher T. Ritchlin
University of Rochester
Patent number: 9,018,358
Issue Date: April 28, 2015


Methods of producing proteins having triple-helix structure
Tetsuo Kase, Akio Kimura, Hiroshi Ueyama, Mizuki Nishihara, Yoko Kisaki
Osaka Prefectural Government
Patent number: 9,018,354
Issue Date: April 28, 2015


Method of treating hyperproliferation of cells using a nucleolin specific aptamer
Pohang University of Science and Technology
Patent number: 9,018,186
Issue Date: April 28, 2015


Method of diagnosing cancer using a nucleolin specific aptamer
Pohang University of Science and Technology
Patent number: 9,018,185
Issue Date: April 28, 2015


Materials and methods for suppressing inflammatory and neuropathic pain
Rajesh Khanna
Indiana University
Patent number: 9,018,173
Issue Date: April 28, 2015


Modification of peptides via S
Bradley L. Pentelute, Alexander M. Spokoyny, Yekui Zou, Chi Zhang
Massachusetts Institute of Technology
Patent number: 9,018,172
Issue Date: April 28, 2015


Peptides for suppressing inflammation
Daniel T. Laskowitz, Hana Dawson, Brad Kolls
Duke University
Patent number: 9,018,169
Issue Date: April 28, 2015


Glucagon analogs exhibiting physiological solubility and stability
Richard D. DiMarchi, David L. Smiley
Indiana University
Patent number: 9,018,164
Issue Date: April 28, 2015


Modulating PDX-1 with PCIF1, methods and uses thereof
Doris Stoffers
University of Pennsylvania
Patent number: 9,018,163
Issue Date: April 28, 2015


Prevention and treatment of inflammation and organ injury after ischemia/reperfusion using MFG-E8
Ping Wang
Feinstein Institute for Medical Research
Patent number: 9,018,157
Issue Date: April 28, 2015


Compositions and methods for generating and screening adenoviral libraries
Shawn E. Lupold, Ronald Rodriguez, Wasim H. Chowdhury, Tarana A. Kudrolli
Johns Hopkins University
Patent number: 9,018,138
Issue Date: April 28, 2015


Gamma satellite insulator sequences and their use in preventing gene silencing
Jung-Hyun Kim, Vladimir L. Larionov, Tom Ebersole
Department of Health and Human Services
Patent number: 9,018,011
Issue Date: April 28, 2015


Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state
Michal Amit, Joseph Itskovitz-Eldor
Technion
Patent number: 9,018,010
Issue Date: April 28, 2015


Three-dimensional scaffold and method of manufacturing the same
Dong-Woo Cho, Jong Young Kim, Jin-Hyung Shim
Pohang University of Science and Technology
Patent number: 9,018,008
Issue Date: April 28, 2015


Method of deriving progenitor cell line
Sai Kiang Lim, Elias Lye
Agency for Science, Technology and Research
Patent number: 9,018,005
Issue Date: April 28, 2015


Method of expanding double negative T cells
Li Zhang, Mei Han, Pouneh Dokouhaki
University Health Network
Patent number: 9,018,004
Issue Date: April 28, 2015


Method to trigger RNA interference
Oregon State University
Patent number: 9,018,002
Issue Date: April 28, 2015


Importation of mitochondrial protein by an enhanced allotopic approach
Marisol Corral-Debrinski, Jose-Alain Sahel, Valerie Kaltimbacher, Crystel Bonnet
Institut National de la Sante et de la Recherche Medicale
Patent number: 9,017,999
Issue Date: April 28, 2015


Expression of proteins in plants
University of Cape Town
Patent number: 9,017,987
Issue Date: April 28, 2015


Non-wild-type organophosphorus acid anhydrolases for enzymatic decontamination
United States Army
Patent number: 9,017,982
Issue Date: April 28, 2015


Sugar-chain modified yeast and method for producing glycoprotein using the same
Hiroko Abe, Kazuya Tomimoto, Yasuko Fujita, Tomoko Iwaki, Yasunori Chiba, Yoshihiro Nakajima, Kenichi Nakayama, Masatoshi Kataoka, Shouki Yatsushiro, Shohei Yamamura
Japan National Institute of Advanced Industrial Science and Technology
Patent number: 9,017,969
Issue Date: April 28, 2015


Biomarker and therapeutic for urinary tract infection
Washington University
Patent number: 9,017,953
Issue Date: April 28, 2015


HIV-1 latency model for high throughput screening
Joseph P. Dougherty, Sofiya Micheva-Viteva, Stuart W. Peltz, Yacov Ron, Annmarie Pacchia
University of Medicine & Dentistry of New Jersey
Patent number: 9,017,935
Issue Date: April 28, 2015


Glucose biofuel cell
Philippe Cinquin, Chantal Gondran, Fabien Giroud, Serge Cosnier
Universite Joseph Fourier
Patent number: 9,017,884
Issue Date: April 28, 2015


Pathway for Th-17 cell development and methods utilizing same
Casey T. Weaver, Paul R. Mangan, Laurie E. Harrington
University of Alabama, Birmingham
Patent number: 9,017,685
Issue Date: April 28, 2015


Diagnosis and treatment of cancer using anti-EREG antibody
Hiroyuki Aburatani, Hirotaka Ito, Kenji Yoshida
University of Tokyo
Patent number: 9,017,684
Issue Date: April 28, 2015


Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
Vafa Shahabi, Anu Wallecha, Paulo C. Maciag, Yvonne Paterson, Nicola Mason, Matthew Seavey
University of Pennsylvania
Patent number: 9,017,660
Issue Date: April 28, 2015


Preparation system and method
National Aeronautics and Space Administration
Patent number: 9,017,621
Issue Date: April 28, 2015


DrugPatentWatch provides competitive intelligence on small-molecule drugs and the 90,000 global patents covering them

Click the patents below for more details, or visit DrugPatentWatch.com for more options.

ABILIFY MAINTENA KIT (aripiprazole)
Otsuka Pharm Co Ltd
Patent number: 5,006,528
Expiration Date: Apr 20, 2015


ABILIFY (aripiprazole)
Otsuka
Patent number: 5,006,528
Expiration Date: Apr 20, 2015


CAVERJECT (alprostadil)
Pharmacia And Upjohn
Patent number: 5,741,523
Expiration Date: Apr 21, 2015


EXUBERA (insulin recombinant human)
Pfizer
Patent number: 5,740,794
Expiration Date: Apr 21, 2015


OXYTROL (oxybutynin)
Actavis Labs Ut Inc
Patent number: 5,601,839
Expiration Date: Apr 26, 2015


OXYTROL FOR WOMEN (oxybutynin)
Bayer Healthcare Llc
Patent number: 5,601,839
Expiration Date: Apr 26, 2015


OXYTROL (oxybutynin)
Actavis Labs Ut Inc
Patent number: 5,834,010
Expiration Date: Apr 26, 2015


OXYTROL FOR WOMEN (oxybutynin)
Bayer Healthcare Llc
Patent number: 5,834,010
Expiration Date: Apr 26, 2015


For more information try a free trial

DrugPatentWatch provides competitive intelligence on small-molecule drugs and the 90,000 global patents covering them

Click the patents below for more details, or visit DrugPatentWatch.com for more options.

ABILIFY MAINTENA KIT (aripiprazole)
Otsuka Pharm Co Ltd
Patent number: 5,006,528
Expiration Date: Apr 20, 2015


ABILIFY (aripiprazole)
Otsuka
Patent number: 5,006,528
Expiration Date: Apr 20, 2015


CAVERJECT (alprostadil)
Pharmacia And Upjohn
Patent number: 5,741,523
Expiration Date: Apr 21, 2015


EXUBERA (insulin recombinant human)
Pfizer
Patent number: 5,740,794
Expiration Date: Apr 21, 2015


OXYTROL FOR WOMEN (oxybutynin)
Bayer Healthcare Llc
Patent number: 5,834,010
Expiration Date: Apr 26, 2015


OXYTROL (oxybutynin)
Actavis Labs Ut Inc
Patent number: 5,601,839
Expiration Date: Apr 26, 2015


OXYTROL FOR WOMEN (oxybutynin)
Bayer Healthcare Llc
Patent number: 5,601,839
Expiration Date: Apr 26, 2015


OXYTROL (oxybutynin)
Actavis Labs Ut Inc
Patent number: 5,834,010
Expiration Date: Apr 26, 2015


For more information try a free trial

TechTransferWatch is a search engine and alert service for licenseable technologies from academic labs, foundations, and government.

Click the patents below for more details, or visit TechTransferWatch.com for more options.

Passive electric field focus system for in vivo and in vitro applications
Jose I. Rey, Richard Gilbert, Mark J. Jaroszeski, Richard Heller
University of South Florida
Patent number: 9,014,800
Issue Date: April 21, 2015



Cyril Falentin, Michel Bregeon, Marie Odile Lucas, Michel Renard
Institut National de la Recherche Agronomique
Patent number: 9,012,718
Issue Date: April 21, 2015


Recovery method of highly pure lactic acid and alkyl lactate
Dong Won Hwang, Jong-San Chang, Young Kyu Hwang, U-Hwang Lee, HyoJin Gwak
Korea Research Institute of Chemical Technology
Patent number: 9,012,685
Issue Date: April 21, 2015


Methods for assaying α-L-iduronidase enzymatic activity
Michael H. Gelb, Sophie Blanchard
University of Washington
Patent number: 9,012,663
Issue Date: April 21, 2015


Antimicrobial compounds and uses thereof
Agency for Science, Technology and Research
Patent number: 9,012,505
Issue Date: April 21, 2015


Pharmaceutical anti-angiogenic composition including a MicroRNA-382 inhibitor
You Mie Lee
Kyungpook National University
Patent number: 9,012,426
Issue Date: April 21, 2015


Methods for the treatment of Leber congenital amaurosis
Jean-Michel Rozet, Antoine Kichler, Isabelle Perrault, Josseline Kaplan, Xavier Gerard, Daniel Scherman, M. Arnold Munnich, Jean-Michel Rozet, Antoine Kichler, Isabelle Perrault, Josseline Kaplan, Xavier Gerard, Daniel Scherman, M. Arnold Munnich
Paris Descartes University
Patent number: 9,012,425
Issue Date: April 21, 2015


Methods and compositions related to eosinophil regulation
Lori A. Wagner, Katrin Szardenings, Gerald J. Gleich, Tarek Aboul-Fadl Mohamed
University of Utah
Patent number: 9,012,419
Issue Date: April 21, 2015


Rapid screening method of translational fusion partners for producing recombinant proteins and translational fusion partners screened therefrom
Korea Research Institute of Bioscience and Biotechnology
Patent number: 9,012,367
Issue Date: April 21, 2015


Chimeric vectors
Dawn E. Bowles, Chengwen Li, Joseph E. Rabinowitz, Josh Grieger, Mavis Agbandje-McKenna, Richard Jude Samulski, Dawn E. Bowles, Chengwen Li, Joseph E. Rabinowitz, Josh Grieger, Mavis Agbandje-McKenna, Richard Jude Samulski
University of North Carolina, Chapel Hill
Patent number: 9,012,224
Issue Date: April 21, 2015


Methods for enhancing genome stability and telomere elongation in embryonic stem cells
Department of Health and Human Services
Patent number: 9,012,223
Issue Date: April 21, 2015


RNA preparations comprising purified modified RNA for reprogramming cells
Katalin Kariko, Drew Weissman, Gary Dahl, Anthony Person, Judith Meis, Jerome Jendrisak
University of Pennsylvania
Patent number: 9,012,219
Issue Date: April 21, 2015


Methods for identifying leukemia stem cells and distinguishing them from normal hematopietic stem cells in patients with acute myeloid leukemia: uses in diagnosis, treatment, and research
Jonathan Michael Gerber, Richard John Jones
Johns Hopkins University
Patent number: 9,012,215
Issue Date: April 21, 2015


Microfluidic device, system, and method for controlled encapsulation of particles or particle clusters
Florence Rivera, Jean Berthier, Sophie Le Vot
Commissariat a l’Energies Atomique et aux Energies Alternatives
Patent number: 9,012,203
Issue Date: April 21, 2015


Micro-bubble plate for patterning biological and non-biological materials
University of California
Patent number: 9,012,193
Issue Date: April 21, 2015


Modified alcohol dehydrogenases for the production of fuels and chemicals
Sabine Bastian, Frances Arnold, Peter Meinhold
California Institute of Technology
Patent number: 9,012,189
Issue Date: April 21, 2015


Use of template switching for DNA synthesis
Alan M. Lambowitz, Sabine Mohr, Travis B. White, Scott Kuersten
University of Texas System
Patent number: 9,012,183
Issue Date: April 21, 2015


Method for mass-producing antifreeze protein derived from polar yeast
Hakjun Kim, Sungho Kang, Junhyuck Lee, Sunggu Lee, Sejong Han, Jongchan Park, Kyoungsun Park
Korea Ocean Research and Development Institute
Patent number: 9,012,179
Issue Date: April 21, 2015


Methods and compositions for improving sugar transport, mixed sugar fermentation, and production of biofuels
, , , , ,
University of Illinois
Patent number: 9,012,177
Issue Date: April 21, 2015


Mutant AOX1 promoters
Franz Hartner, Anton Glieder
Graz University of Technology
Patent number: 9,012,175
Issue Date: April 21, 2015


Split peroxidases and methods of use
Massachusetts Institute of Technology
Patent number: 9,012,170
Issue Date: April 21, 2015


Anti-bacterial peptides and methods of treating diseases using same
Hanna Engelberg-Kulka, Ilana Kolodkin-Gal
Hebrew University of Jerusalem
Patent number: 9,012,152
Issue Date: April 21, 2015


Method of enzymatic gene chip detection kit
Fooyin University Hospital
Patent number: 9,012,147
Issue Date: April 21, 2015


Protein tyrosine phosphatase mutations in cancers
Zhenghe Wang, Victor Velculescu, Kenneth W. Kinzler, Bert Vogelstein
Johns Hopkins University
Patent number: 9,012,145
Issue Date: April 21, 2015


Polymorphisms in genes affecting ace-related disorders and uses thereof
Wolfgang Sadee, Andrew D. Johnson, Danxin Wang, Audrey C. Papp
Ohio State University
Patent number: 9,012,143
Issue Date: April 21, 2015


Sequence-specific detection of nucleotide sequences
Mark Danielsen, Eugene A. Davidson, Kenneth L. Dretchen, Traci K. Pals
Georgetown University
Patent number: 9,012,142
Issue Date: April 21, 2015


Method for enzymatic treatment, device and kit used the same
Industrial Technology Research Institute (ITRI)
Patent number: 9,011,917
Issue Date: April 21, 2015


Use of specific peptides in the preparation of a medicament for the treatment of monoclonal gammopathy of undetermined significance (MGUS) or of smoldering multiple myeloma (SMM)
Michael Hundemer, Olaf Christensen
Heidelberg University
Patent number: 9,011,867
Issue Date: April 21, 2015


RNA interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by DNA and transfected dendritic cell vaccines
Tzyy-Choou Wu, Chien-Fu Hung
Johns Hopkins University
Patent number: 9,011,866
Issue Date: April 21, 2015


Human cystathionine β-synthase variants and methods of production thereof
University of Colorado
Patent number: 9,011,844
Issue Date: April 21, 2015


Screening tool for antiviral agents
Karoly Toth, William S. M. Wold
Saint Louis University
Patent number: 9,011,820
Issue Date: April 21, 2015


Manufacturing three-dimensional scaffolds using electrospinning at low temperatures
Meng Fatt Leong, Tze Chiun Lim, Kerm Sin Chian
Nanyang Technological University
Patent number: 9,011,754
Issue Date: April 21, 2015


Journal of Commercial Biotechnology This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

Current and future prospects for the global biotechnology industry

Go to paper

ABSTRACT: The number of biotechnology compounds has been increasing steadily over the past 20 years, reflecting the key contribution that biotechnology is now making to healthcare. Recombinant DNA technology has been used to develop a number of therapeutic proteins, including antibodies, cytokines, hormones and vaccines for use in tackling and diagnosing a range of disorders...

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

  • Management
  • Policy
  • Finance
  • Law
  • Regulation
  • Bioethics

For more information, see the Journal of Commercial Biotechnology website

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below.

Susan Kling Finston

Nascent life sciences start-ups in the BRICS and other emerging markets face continuing fundraising hurdles, as discussed here and more recently here. So while there have been increasing calls for India’s small-scale entrepreneurs to move from ‘jugaad’ to more Israeli-style start-ups, access to capital has not kept pace with India’s appetite for innovation. Understanding just how limited India’s public funding is for biotech start-ups may help to explain the importance of this issue.

The Indian Department of Biotechnology (DBT) provides the lion’s share of domestic funding for R&D-Intensive Micro-Small & Medium Enterprises (MSMEs). Not taking into account limitations in actual disbursement of budgeted funds, the DBT’s stated funding for the SBIRI, BIPP and other R&D programs amounted to less than $15 million annually in recent years: “For 2013-14, the allocations are merely 90 crores,” (p. 44). Of this total, the lion’s share historically has aided established pharmaceutical / biotech companies.  

Accordingly, the Modi Government should look beyond public sectors funding schemes for biotech startups, where tax incentives to energize Angel Investors may play an important role in dramatically increasing funding for innovative start-ups. Both Israel and the US provide R&D Investment tax credits that serve as effective incentives for funding ‘high risk-high reward’ ventures, with immediate benefits to Angels who traditionally provide seed funding to start-ups at earlier stages than VCs. 

Issues relating to broader tax reforms and the need for tax incentives for high net worth individuals (HNWI) to create a broad class of Angel Investors surfaced over the course of the April 15th CSIS program: Deepening the U.S.-India Commercial Partnership: The First Year of the Modi Government, co-organized by the Wadhwani Foundation and the Ananta Aspen Centre. India’s private sector represents a huge, untapped source of capital to support job creation through funding of R&D-intensive MSMEs.  With a total of 14,800 multimillionaires and 2,700 multimillionaires in Mumbai alone, India ranks in 8th place globally in terms of the number of multimillionaires and is home to the 4th largest number of billionaires around the world.

India ranks in 8th place globally in terms of the number of multimillionaires and is home to the 4th largest number of billionaires around the world

With the right tax incentives, these High Net Worth Individuals (HNWIs) may take flight as a new Angel Investor class, easily surpassing limited public funds available to India’s R&D intensive MSMEs. Giving Angel Investors their wings could help an unprecedented number of MSME innovators, leading to a virtuous circle of job creation and development of new pharmaceutical and biotechnology products that are ‘made in India.’

More information on investment tax credits and how India may benefit through selective adaptation of Israeli and US policies for R&D intensive MSMEs may be found in the Wadhwani Foundation’s Innovation Blueprint Study, available for download here.

 

About the author:
President of Finston Consulting LLC since 2005, Susan works with innovative biotechnology and other clients ranging from start-up to Fortune-100, providing support for legal, transactional, policy and “doing business” issues. Susan has extensive background and special expertise relating to intellectual property and knowledge-economy issues in advanced developing countries including India and South Asia, Latin America and the Middle East North Africa (MENA) region. She also works with governments, and NGOs on capacity building and related educational programs through BayhDole25. Together with biotechnology pioneer Ananda Chakrabarty, she also is co-founder of Amrita Therapeutics Ltd., an emerging biopharmaceutical company based in India with cancer peptide drugs entering in vivo research. Previous experience includes 11 years in the U.S Foreign Service with overseas tours in London, Tel Aviv, and Manila and at the Department of State in Washington DC. For more information on latest presentations and publications please visit finstonconsulting.com.